FOXP1 and prostate cancer: In the TCGA prostate cancer cohort4, combined FOXP1 and PTEN loss is also associated with biochemical recurrence, compared to loss of either gene alone or no loss (P = 0.029, Cox regression; HR, 2.81; 95% CI, 1.11, 7.08; Table 1, Fig. 4b).